会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • NON-NUCLEOTIDE PHOSPHOROUS ESTER OLIGOMERS
    • 非核苷酸磷酸酯低聚物
    • WO1997028168A1
    • 1997-08-07
    • PCT/US1997001060
    • 1997-01-22
    • PHARMAGENICS, INC.
    • PHARMAGENICS, INC.GENTLES, Robert, G.COOK, Alan, F.RUDOLPH, Morris, J.FATHI, Reza
    • C07F09/58
    • C07F9/65616C07F9/1411C07F9/143C07F9/145C07F9/2408C07F9/2416C07F9/242C07F9/5728C07F9/58C07F9/6506C07F9/650952C07F9/6539C07F9/65515C07F9/6561C40B40/00Y02P20/55
    • A phosphorus ester oligomer having structure (I) wherein A can be the same or different in each monomeric unit and each is independently selected from the group consisting of oxygen, sulfur, lower alkyl, substituted or unsubstituted alkylamino, substituted or unsubstituted arylamino and aminoalkyl; B1 and B2 can be the same or different and each is independently selected from hydrogen, lower alkyl, a labelling group, a protecting group, a phosphoramidate or a phosphomonoester; R1 can be the same or different in each monomeric unit, and in at least one of the non-nucleotide monomeric units, R1 is independently selected from the group consisting of a condensation product of (i) a non-vicinal diol attached to a hydrogen bond donor functionality; (ii) a hydrogen bond acceptor selected from an ether, a purine or pyrimidine substituted 1,2-diol or a disubstituted heterocycle; (iii) a non-vicinal diol attached to a hydrophobic functionality or a vicinal diol attached to an aliphatic or alicyclic hydrophobic functionality; (iv) a diol attached to a ring substituted anionic functionality and (v) a cationic moiety attached to a non-vicinal or alicyclic diol, any of which can further include a detectable label, and n is at least one. Preferred R1 moieties include condensation products of heterocyclic diols, alicyclic diols, and polycyclic diols. Also the non-nucleotide monomers thereof, combinatorial library mixtures of the oligomers and the use of the oligomers as selective target-binding compounds.
    • 具有结构(I)的磷酯低聚物,其中A在每个单体单元中可以相同或不同,并且各自独立地选自氧,硫,低级烷基,取代或未取代的烷基氨基,取代或未取代的芳基氨基和氨基烷基; B1和B2可以相同或不同,各自独立地选自氢,低级烷基,标记基团,保护基,氨基磷酸酯或磷酸酯酯; R 1可以在每个单体单元中相同或不同,并且在至少一个非核苷酸单体单元中,R 1独立地选自以下组中的缩合产物:(i)连接于氢的非连位二醇 债券供体功能; (ii)选自醚,嘌呤或嘧啶取代的1,2-二醇或二取代杂环的氢键受体; (iii)连接到疏水官能团的非连位二醇或连接到脂族或脂环族疏水官能团的连位二醇; (iv)连接到环取代的阴离子官能团的二醇和(v)连接到非邻位或脂环族二醇上的阳离子部分,其中任何一个可以进一步包括可检测标记,并且n是至少一个。 优选的R1部分包括杂环二醇,脂环族二醇和多环二醇的缩合产物。 还有其非核苷酸单体,低聚物的组合文库混合物以及低聚物作为选择性靶结合化合物的用途。
    • 2. 发明申请
    • NON-NUCLEOTIDE PHOSPHORUS ESTER OLIGOMERS
    • 非核苷酸磷酸酯低聚物
    • WO1996022297A1
    • 1996-07-25
    • PCT/US1996000369
    • 1996-01-03
    • PHARMAGENICS, INC.
    • PHARMAGENICS, INC.GENTLES, Robert, G.COOK, Alan, F.RUDOLPH, M., JonathanFATHI, Reza
    • C07F09/09
    • C07F9/6578C07B59/004C07F9/1411C07F9/1414C07F9/143C07F9/144C07F9/145C07F9/2408C07F9/2416C07F9/242C07F9/5728C07F9/58C07F9/6506C07F9/650952C07F9/6539C07F9/65515C07F9/6561C07F9/65616C40B40/00Y02P20/55
    • A phosphorus ester oligomer having structure (I) wherein A can be the same or different in each monomeric unit and each is independently selected from the group consisting of oxygen, sulfur, lower alkyl, alkyl- or aryl-substituted amino and aminoalkyl; B1 and B2 can be the same or different and each is independently selected from hydrogen, lower alkyl, a labelling group, a protecting group, a phosphoramidate or a phosphomonoester; R1 can be the same or different in each monomeric unit, and in at least one of the non-nucleotide monomeric units, R1 is independently selected from the group consisting of a condensation product of (i) a non-vicinal diol attached to a hydrogen bond donor functionality; (ii) a hydrogen bond acceptor selected from an ether, a purine or pyrimidine substituted 1,2-diol or a disubstituted heterocycle; (iii) a non-vicinal diol attached to a hydrophobic functionality or a vicinal diol attached to an aliphatic or alicyclic hydrophobic functionality; (iv) a diol attached to a ring substituted anionic functionality and (v) a cationic moiety attached to a non-vicinal or alicyclic diol, any of which can further include a detectable label, and n is at least one. Preferred R1 moieties include condensation products of heterocyclic diols, alicyclic diols, and polycyclic diols. Also the non-nucleotide monomers thereof, combinatorial library mixtures of the oligomers and the use of the oligomers as selective target-binding compounds.
    • 具有结构(I)的磷酯低聚物,其中A在每个单体单元中可以相同或不同,并且各自独立地选自氧,硫,低级烷基,烷基或芳基取代的氨基和氨基烷基; B1和B2可以相同或不同,各自独立地选自氢,低级烷基,标记基团,保护基,氨基磷酸酯或磷酸酯酯; R 1可以在每个单体单元中相同或不同,并且在至少一个非核苷酸单体单元中,R 1独立地选自以下组中的缩合产物:(i)连接于氢的非连位二醇 债券供体功能; (ii)选自醚,嘌呤或嘧啶取代的1,2-二醇或二取代杂环的氢键受体; (iii)连接到疏水官能团的非连位二醇或连接到脂族或脂环族疏水官能团的连位二醇; (iv)连接到环取代的阴离子官能团的二醇和(v)连接到非邻位或脂环族二醇上的阳离子部分,其中任何一个可以进一步包括可检测标记,并且n是至少一个。 优选的R1部分包括杂环二醇,脂环族二醇和多环二醇的缩合产物。 还有其非核苷酸单体,低聚物的组合文库混合物以及低聚物作为选择性靶结合化合物的用途。